Clinical Trials Logo

Rheumatoid Arthritis clinical trials

View clinical trials related to Rheumatoid Arthritis.

Filter by:

NCT ID: NCT01717846 Withdrawn - Clinical trials for Rheumatoid Arthritis

Effect on Orencia (Abatacept) on the Apoptosis of T Cells, B Cells and APC Cells in Rheumatoid Arthritis

RA
Start date: December 2012
Phase: Phase 4
Study type: Interventional

This proposal will test the hypothesis that Orencia affects apoptosis and apoptosis related genes/biomarkers in vivo in rheumatoid arthritis (RA) patients.

NCT ID: NCT01694693 Withdrawn - Clinical trials for Rheumatoid Arthritis

Description of Joint Population and Assessment of Impact on Health Status of Orencia in Patients With Rheumatoid Arthritis in France. A Database Analysis Based on SFR's ORA Long-term Cohort Study

Start date: January 31, 2018
Phase: N/A
Study type: Observational

Database analysis: - To describe how Orencia is prescribed in France in Rheumatoid Arthritis (RA) - To describe joint population of Orencia - To assess the impact of the treatment on health status of the treated population as assessed by morbid-mortality criteria - To describe therapeutic strategies and use of health services

NCT ID: NCT01692457 Withdrawn - Clinical trials for Rheumatoid Arthritis

A Study to Assess the Safety and Effectiveness of Golimumab in Filipino Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Start date: July 2013
Phase: Phase 4
Study type: Observational

The purpose of this study is to assess the safety and effectiveness of golimumab for the treatment of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis among Filipino patients.

NCT ID: NCT01652937 Withdrawn - Clinical trials for Rheumatoid Arthritis

BIIB057 in Subjects With Rheumatoid Arthritis and Inadequate Response to Disease-Modifying Antirheumatic Drugs

EMBRACE
Start date: August 2012
Phase: Phase 2
Study type: Interventional

Phase II study designed to evaluate the safety and efficacy of BIIB057 in Subjects with Rheumatoid Arthritis who have experienced an Inadequate Response to Disease-Modifying Antirheumatic Drugs (DMARDs).

NCT ID: NCT01463566 Withdrawn - Clinical trials for Rheumatoid Arthritis

Gender Solutions Natural Knee Post-Market Study

Start date: January 2012
Phase:
Study type: Observational

This is a prospective multicenter study of the Gender Solutions Natural Knee Flex System when used in primary total knee arthroplasty. The purpose of the study is to obtain short-, Mid-, and long-term clinical outcomes and implant survivorship data for the Gender Solutions Natural Knee Flex System.

NCT ID: NCT01462240 Withdrawn - Clinical trials for Rheumatoid Arthritis

LPS Flex Porous Femoral Components

Start date: May 20, 2008
Phase:
Study type: Observational

This is a prospective multicenter study of the LPS-Flex Porous Femoral Components when used in primary total knee arthroplasty. The purpose of the study is to obtain short-, mid-, and long-term clinical outcomes and implant survivorship data for the NexGen LPS-Flex Porous Femoral components.

NCT ID: NCT01394913 Withdrawn - Clinical trials for Rheumatoid Arthritis

Comparison of Two Etanercept Regimens (REUMATOCEPT® Versus ENBREL®) for Treatment of Rheumatoid Arthritis

Start date: August 2013
Phase: Phase 3
Study type: Interventional

This study is a comparison of safety and efficacy of two etanercept regimens (REUMATOCEPT® versus ENBREL®) for treatment of Rheumatoid Arthritis.

NCT ID: NCT01221636 Withdrawn - Clinical trials for Rheumatoid Arthritis

Pharmacokinetic Study to Compare the Blood Levels of Low vs High Metal Manufacture of Abatacept

Start date: October 2010
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine whether the blood levels of abatacept drug product manufactured using High Metals and using Low Metals are comparable in healthy subjects.

NCT ID: NCT01090570 Withdrawn - Clinical trials for Rheumatoid Arthritis

Safety, Pharmacokinetic (PK), Pharmcodynamic (PD), and Drug-Drug Interaction of PLX3397 in Patients With Rheumatoid Arthritis Who Are Receiving Methotrexate

Start date: May 2010
Phase: Phase 1
Study type: Interventional

PLX3397 is a selective inhibitor of Fms and Kit activity. The objective of this study is to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and drug-drug interaction (DDI) of orally administered PLX3397 during 2 weeks of dosing in patients with rheumatoid arthritis (RA) who are on maintenance methotrexate. This study is planned to provide data to inform dose selection for a subsequent 12 week dose ranging study in RA.

NCT ID: NCT01067430 Withdrawn - Clinical trials for Rheumatoid Arthritis

Comparison of the Effect of Etoricoxib and Diclofenac on Early Morning Activity in Rheumatoid Arthritis (RA)

Start date: April 2010
Phase: Phase 4
Study type: Interventional

The purpose of this study is to explore the effect of Etoricoxib compared to Diclofenac on physical activity in RA subjects with early morning pain and stiffness.